TRAIL、TRAIL-R在原发性肝癌及其癌旁组织中的表达

Expression of TRAIL and its receptors in primary hepatic carcinoma

目的检测肿瘤坏死因子相关凋亡诱导配体(TRAIL)及其受体在原发性肝癌(PHC)及癌旁组织中的表达。方法收集PHC及癌旁组织各30例,采用半定量RT-PCR方法,对TRAIL及其受体的表达作半定量检测。结果(1)30例癌组织及癌旁组织中均有TRAIL及其死亡受体4(DR4)、死亡受体5(DR5)、“诱骗”受体1,2(DcR1、DcR2)的表达。(2)TRAIL、DcR1及DcR2在癌组织中的表达量较之癌旁组织明显降低(P<0.01),而DR4、DR5的表达量则高于癌旁组织;(3)PHC组织中4种受体之间,DR4及DR5的表达量明显高于DcR1及DcR2,且PHC组织中4种受体间的表达量存在相关性。结论PHC及其癌旁组织中均存在TRAIL及其受体的表达,且有表达量的差异。

Objective To investigate the expression of tumor necrosis factor-related apoptosisinducing ligand （TRAIL） and its receptors in patients with primary hepatic carcinoma （PHC）. Methods TRAII. and its receptors were assayed by semiquantitive RTPCR in 30 PHC specimens, and 30 specimens of adjacent non-malignant liver tissues. Results TRAII. and its receptors were detectable in all of the tumors and adjacent non-malignant tissues. Expressions of TRAII., DcR1, DcR2 were lower, but those of death receptor 4（DR4） and DR5 were higher in hepatoma tissues than those in the adjacent non-malignant tissues. Expressions of DR4 and DR5 were higher than those of DcR1 and DcR2 in hepatoma tissues,which were not significantly different in the adjacent non-malignant tissues. There was a correlation among the expression TRAIl. receptors. Conclusion TRAIL and its receptors are expressed in both hepatoma tissues and adjacent non-malignant tissues with different expression levels.